Pharmacogenomics of COVID-19 therapies

A new global pandemic of coronavirus disease 2019 (COVID-19) has resulted in high mortality and morbidity. Currently numerous drugs are under expedited investigations without well-established safety or efficacy data. Pharmacogenomics may allow individualization of these drugs thereby improving effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Takuto, Luzum, Jasmine A., Nicol, Melanie R., Jacobson, Pamala A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435176/
https://www.ncbi.nlm.nih.gov/pubmed/32864162
http://dx.doi.org/10.1038/s41525-020-00143-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435176/
https://www.ncbi.nlm.nih.gov/pubmed/32864162
http://dx.doi.org/10.1038/s41525-020-00143-y

Ejemplares similares